This fact is reflected in the work of Schorling et al. (2019), in which 20 SMA patients were retested for their SMN2 dosage using new DNA samples and 45% of the results were discrepant in comparison with the initial ones [55]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.